{"id":450864,"date":"2021-03-04T09:18:03","date_gmt":"2021-03-04T14:18:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450864"},"modified":"2021-03-04T09:18:03","modified_gmt":"2021-03-04T14:18:03","slug":"biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/","title":{"rendered":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Westport, CT, March  04, 2021  (GLOBE NEWSWIRE) &#8212; <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:18.75pt;margin-bottom:18.75pt\">\n          <strong>The patent is exclusively licensed from <\/strong><br \/>\n          <strong>Mayo Foundation for Medical Education and Research <\/strong>\n        <\/li>\n<li style=\"margin-top:18.75pt;margin-bottom:18.75pt\">\n          <strong>Claims address methods <\/strong><br \/>\n          <strong>and materials for improving the treatment of hypertension<\/strong>\n        <\/li>\n<li style=\"margin-top:18.75pt;margin-bottom:18.75pt\">\n          <strong>Fifteen additional licensed worldwide patent applications are pending, generally covering electroporation and stimulation<\/strong>\n        <\/li>\n<\/ul>\n<p>BioSig Technologies, Inc. (NASDAQ: BSGM) (\u201cBioSig\u201d or the \u201cCompany\u201d), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research. <\/p>\n<p>The recently allowed patent application number 16\/805,017 entitled <em>&#8220;<\/em><em>Systems and Methods for Electroporation<\/em><em>&#8220;<\/em> was filed on February 28, 2020. The patent describes and claims methods and materials for improving the treatment of hypertension via electroporation of nerves in the renal area. Electroporation is an emerging technique that has demonstrated efficacy in treatments for several critical conditions and is currently being evaluated for the treatments of autonomic nervous disorders, including hyper- and hypotension \/ syncope.<\/p>\n<p>The allowed patent application complements BioSig\u2019s expanding patent portfolio, which now includes nine allowed\/issued patents. Sixteen additional worldwide utility patent applications are pending covering various aspects of its PURE EP\u2122 System for recording, measuring, calculating, and displaying of electrocardiograms during cardiac ablation procedures. The Company has two additional pending U.S. patent applications directed to artificial intelligence (AI).\u00a0 BioSig has 24 allowed\/issued worldwide design patents covering various features of its display screens and graphical user interface for enhanced visualization of biomedical signals.\u00a0Finally, in addition to the patent referenced above, BioSig has exclusive licenses to 15 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending. These 15 applications are generally directed to electroporation and stimulation. <\/p>\n<p>&#8220;We are pleased to announce this newest patent allowance which creates a patent foundation for the development of our N-SENSE\u2122 platform technology. Our first neurostimulation product aims to address a vast market of neurological conditions through a proprietary sensing design and algorithms tailored to specific applications. Electroporation is a novel technique that has significantly advanced cancer treatments and has shown promise in treating cardiovascular disease. We look forward to exploring it further with our research partners,\u201d commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.<\/p>\n<p>\n        <strong>About BioSig Technologies<br \/><\/strong>BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to\u00a0improve signal fidelity and uncover the full range of ECG and intra-cardiac signals\u00a0(<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HTuwWKq6-frJn5V5OFcksN1xEk_9undy3gcHayPkediZTOna_K8sG60ulCD00qkQVtV3nWZyOhGUpU6f9hu-tQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.biosig.com<\/u><\/a>).<\/p>\n<p>The Company\u2019s first product,\u00a0PURE EP\u2122 System\u00a0is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.<\/p>\n<p>\n        <strong>Forward-looking Statements <\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at http:\/\/www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\u00a0 <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/80fc8679-882c-4225-8aab-fc8244cec304\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Andrew Ballou\r\nBioSig Technologies, Inc. \r\nVice President, Investor Relations \r\n54 Wilton Road, 2nd floor\r\nWestport, CT 06880\r\naballou@biosigtech.com\r\n203-409-5444, x133\r\n\r\n<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) &#8212; The patent is exclusively licensed from Mayo Foundation for Medical Education and Research Claims address methods and materials for improving the treatment of hypertension Fifteen additional licensed worldwide patent applications are pending, generally covering electroporation and stimulation BioSig Technologies, Inc. (NASDAQ: BSGM) (\u201cBioSig\u201d or the \u201cCompany\u201d), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research. The recently allowed patent application number 16\/805,017 entitled &#8220;Systems and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) &#8212; The patent is exclusively licensed from Mayo Foundation for Medical Education and Research Claims address methods and materials for improving the treatment of hypertension Fifteen additional licensed worldwide patent applications are pending, generally covering electroporation and stimulation BioSig Technologies, Inc. (NASDAQ: BSGM) (\u201cBioSig\u201d or the \u201cCompany\u201d), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research. The recently allowed patent application number 16\/805,017 entitled &#8220;Systems and &hellip; Continue reading &quot;BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T14:18:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary\",\"datePublished\":\"2021-03-04T14:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/\"},\"wordCount\":758,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/\",\"name\":\"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\",\"datePublished\":\"2021-03-04T14:18:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/","og_locale":"en_US","og_type":"article","og_title":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk","og_description":"Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) &#8212; The patent is exclusively licensed from Mayo Foundation for Medical Education and Research Claims address methods and materials for improving the treatment of hypertension Fifteen additional licensed worldwide patent applications are pending, generally covering electroporation and stimulation BioSig Technologies, Inc. (NASDAQ: BSGM) (\u201cBioSig\u201d or the \u201cCompany\u201d), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research. The recently allowed patent application number 16\/805,017 entitled &#8220;Systems and &hellip; Continue reading \"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T14:18:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary","datePublished":"2021-03-04T14:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/"},"wordCount":758,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/","name":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=","datePublished":"2021-03-04T14:18:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDQ3OCM0MDQ4NjA5IzIwMTgwNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-awarded-u-s-patent-claims-for-its-neuroclear-subsidiary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioSig Awarded U.S. Patent Claims for its NeuroClear\u2122 Subsidiary"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}